Cancer BiologyCellsPeer-reviewed
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer
Sajid Ullah Khan, Lin Sen Cao, Janet S. Wiegand…·Daohong Zhou
This paper evaluates a dual BCL-xL/BCL-2 degrader, 753b, showing it effectively reduces tumor viability and growth in SCLC models while avoiding platelet toxicity seen with navitoclax.
43 citationstop 3%